FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082667714> ?p ?o ?g. }

• W3082667714 endingPage "1987" @default.
• W3082667714 startingPage "1987" @default.
• W3082667714 abstract "T cell-driven inflammation plays a critical role in the initiation and progression of atherosclerosis. The co-inhibitory protein Cytotoxic T-Lymphocyte Associated protein (CTLA) 4 is an important negative regulator of T cell activation. Here, we studied the effects of the antibody-mediated inhibition of CTLA4 on experimental atherosclerosis by treating 6–8-week-old Ldlr−/− mice, fed a 0.15% cholesterol diet for six weeks, biweekly with 200 μg of CTLA4 antibodies or isotype control for six weeks. 18F-fluorodeoxyglucose Positron Emission Tomography—Computed Tomography showed no effect of the CTLA4 inhibition of activity in the aorta, spleen, and bone marrow, indicating that monocyte/macrophage-driven inflammation was unaffected. Correspondingly, flow cytometry demonstrated that the antibody-mediated inhibition of CTLA4 did not affect the monocyte populations in the spleen. αCTLA4 treatment induced an activated T cell profile, characterized by a decrease in naïve CD44−CD62L+CD4+ T cells and an increase in CD44+CD62L− CD4+ and CD8+ T cells in the blood and lymphoid organs. Furthermore, αCTLA4 treatment induced endothelial activation, characterized by increased ICAM1 expression in the aortic endothelium. In the aortic arch, which mainly contained early atherosclerotic lesions at this time point, αCTLA4 treatment induced a 2.0-fold increase in the plaque area. These plaques had a more advanced morphological phenotype and an increased T cell/macrophage ratio, whereas the smooth muscle cell and collagen content decreased. In the aortic root, a site that contained more advanced plaques, αCTLA4 treatment increased the plaque T cell content. The short-term antibody-mediated inhibition of CTLA4 thus accelerated the progression of atherosclerosis by inducing a predominantly T cell-driven inflammation, and resulted in the formation of plaques with larger necrotic cores and less collagen. This indicates that existing therapies that are based on αCTLA4 antibodies may promote CVD development in patients." @default.
• W3082667714 created "2020-09-08" @default.
• W3082667714 creator A5007050875 @default.
• W3082667714 creator A5014721757 @default.
• W3082667714 creator A5035597774 @default.
• W3082667714 creator A5049641098 @default.
• W3082667714 creator A5059068863 @default.
• W3082667714 creator A5066198455 @default.
• W3082667714 creator A5068007728 @default.
• W3082667714 creator A5069173292 @default.
• W3082667714 creator A5081411192 @default.
• W3082667714 date "2020-08-29" @default.
• W3082667714 modified "2023-10-15" @default.
• W3082667714 title "Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice" @default.
• W3082667714 cites W1997208476 @default.
• W3082667714 cites W2001537535 @default.
• W3082667714 cites W2009487870 @default.
• W3082667714 cites W2049126749 @default.
• W3082667714 cites W2073776582 @default.
• W3082667714 cites W2077579869 @default.
• W3082667714 cites W2104302704 @default.
• W3082667714 cites W2110926368 @default.
• W3082667714 cites W2110947961 @default.
• W3082667714 cites W2116999983 @default.
• W3082667714 cites W2127514489 @default.
• W3082667714 cites W2129819015 @default.
• W3082667714 cites W2130278873 @default.
• W3082667714 cites W2161765882 @default.
• W3082667714 cites W2204491745 @default.
• W3082667714 cites W2317660163 @default.
• W3082667714 cites W2589957432 @default.
• W3082667714 cites W2606382560 @default.
• W3082667714 cites W2625940201 @default.
• W3082667714 cites W2776490115 @default.
• W3082667714 cites W2781337213 @default.
• W3082667714 cites W2787045728 @default.
• W3082667714 cites W2789588679 @default.
• W3082667714 cites W2792636658 @default.
• W3082667714 cites W2886756349 @default.
• W3082667714 cites W2890364529 @default.
• W3082667714 cites W2952065098 @default.
• W3082667714 cites W2954146739 @default.
• W3082667714 cites W2968462573 @default.
• W3082667714 cites W2972338824 @default.
• W3082667714 cites W2976744492 @default.
• W3082667714 cites W2979167769 @default.
• W3082667714 cites W3043703771 @default.
• W3082667714 doi "https://doi.org/10.3390/cells9091987" @default.
• W3082667714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7565685" @default.
• W3082667714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32872393" @default.
• W3082667714 hasPublicationYear "2020" @default.
• W3082667714 type Work @default.
• W3082667714 sameAs 3082667714 @default.
• W3082667714 citedByCount "32" @default.
• W3082667714 countsByYear W30826677142020 @default.
• W3082667714 countsByYear W30826677142021 @default.
• W3082667714 countsByYear W30826677142022 @default.
• W3082667714 countsByYear W30826677142023 @default.
• W3082667714 crossrefType "journal-article" @default.
• W3082667714 hasAuthorship W3082667714A5007050875 @default.
• W3082667714 hasAuthorship W3082667714A5014721757 @default.
• W3082667714 hasAuthorship W3082667714A5035597774 @default.
• W3082667714 hasAuthorship W3082667714A5049641098 @default.
• W3082667714 hasAuthorship W3082667714A5059068863 @default.
• W3082667714 hasAuthorship W3082667714A5066198455 @default.
• W3082667714 hasAuthorship W3082667714A5068007728 @default.
• W3082667714 hasAuthorship W3082667714A5069173292 @default.
• W3082667714 hasAuthorship W3082667714A5081411192 @default.
• W3082667714 hasBestOaLocation W30826677141 @default.
• W3082667714 hasConcept C154317977 @default.
• W3082667714 hasConcept C159654299 @default.
• W3082667714 hasConcept C167672396 @default.
• W3082667714 hasConcept C185592680 @default.
• W3082667714 hasConcept C202751555 @default.
• W3082667714 hasConcept C203014093 @default.
• W3082667714 hasConcept C2776090121 @default.
• W3082667714 hasConcept C2776914184 @default.
• W3082667714 hasConcept C2780007613 @default.
• W3082667714 hasConcept C2780931953 @default.
• W3082667714 hasConcept C2781184567 @default.
• W3082667714 hasConcept C55493867 @default.
• W3082667714 hasConcept C71924100 @default.
• W3082667714 hasConcept C86803240 @default.
• W3082667714 hasConcept C8891405 @default.
• W3082667714 hasConceptScore W3082667714C154317977 @default.
• W3082667714 hasConceptScore W3082667714C159654299 @default.
• W3082667714 hasConceptScore W3082667714C167672396 @default.
• W3082667714 hasConceptScore W3082667714C185592680 @default.
• W3082667714 hasConceptScore W3082667714C202751555 @default.
• W3082667714 hasConceptScore W3082667714C203014093 @default.
• W3082667714 hasConceptScore W3082667714C2776090121 @default.
• W3082667714 hasConceptScore W3082667714C2776914184 @default.
• W3082667714 hasConceptScore W3082667714C2780007613 @default.
• W3082667714 hasConceptScore W3082667714C2780931953 @default.
• W3082667714 hasConceptScore W3082667714C2781184567 @default.
• W3082667714 hasConceptScore W3082667714C55493867 @default.
• W3082667714 hasConceptScore W3082667714C71924100 @default.
• W3082667714 hasConceptScore W3082667714C86803240 @default.

• next